Clinical trial
Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary…
NCT00152997 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00152997 |
|---|---|
| Title | Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome |
| Official title | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Pramipexole 0.125 mg tablets, Pramipexole 0.125 mg tablets Placebo |
| Enrollment | 41 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 31, 2013 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: